BLA 103000 · Allergan
Botox Cosmetic
Onabotulinumtoxina · Single-Use · Acetylcholine Release Inhibitor; Neuromuscular Blocker
NovelOrphanLast checked: Nov 20, 2026Latest source record: Oct 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Dec 9, 1991
Approved uses
25
Original approval plus efficacy supplements
Registered trials
1,077
324 Phase 3, 72 recruiting
FAERS reports
77,970
15,443 serious, 2,225 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to the se symptoms. In unapproved uses and in approved indications, cases of spread of effect...
What it is approved for
From the label in effect Feb 2, 2026.
BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) 1.1 Adult Bladder Dysfunction Overactive Bladder BOTOX for injection is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency, in...
Mechanism: BOTOX blocks neuromuscular transmission by binding to acceptor sites on motor or autonomic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. When injected intramuscularly at therapeutic doses, BOTOX produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity. In addition, the muscle may atrophy, axonal sprouting may occur, and...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 18, 2024 Supplement 5331 · Efficacy Medication GuideLabelLetter
- Aug 11, 2023 Supplement 5325 · Efficacy LetterLabel
- Jul 28, 2021 Supplement 5320 · Efficacy LabelLetterReview
- Feb 9, 2021 Supplement 5318 · Efficacy LabelLetter
- Jul 8, 2020 Supplement 5315 · Efficacy OrphanLetterLabel
- Oct 18, 2019 Supplement 5310 · Efficacy LabelLetter
- Jun 20, 2019 Supplement 5309 · Efficacy · priority review LabelLetter
- Sep 12, 2018 Supplement 5308 · Efficacy LetterLabelPediatric Medical Review
- Oct 2, 2017 Supplement 5303 · Efficacy LabelLetter
- Apr 4, 2017 Supplement 5298 · Efficacy LabelLetter
- Apr 4, 2017 Supplement 5296 · Efficacy LabelLetter
- Apr 4, 2017 Supplement 5297 · Efficacy LabelLetter
- Feb 4, 2016 Supplement 5294 · Efficacy Letter
- Jan 21, 2016 Supplement 5252 · Efficacy LabelLetter
- Apr 17, 2015 Supplement 5282 · Efficacy LabelLetter
- Sep 11, 2013 Supplement 5260 · Efficacy LabelLetter
- Jan 18, 2013 Supplement 5251 · Efficacy LabelLetter
- Aug 24, 2011 Supplement 5232 · Efficacy LabelReviewLetter
- Oct 15, 2010 Supplement 5215 · Efficacy ReviewLetterLabel
- Mar 26, 2010 Supplement 5129 · Efficacy
- Mar 9, 2010 Supplement 5189 · Efficacy · priority review ReviewLabelLetter
- Jul 19, 2004 Supplement 5050 · Efficacy LabelReviewLetter
- Apr 12, 2002 Supplement 5000 · Efficacy ReviewLetterLabel
- Dec 21, 2000 Supplement 1004 · Efficacy OrphanReviewLetter
- Dec 9, 1991 Original approval · Type 1 - New Molecular Entity Other Important Information from FDA
5 products under this application
- BOTOX COSMETIC · OnabotulinumtoxinA 100 UNITS/VIAL · VIAL, SINGLE-USE · Prescription
- BOTOX · OnabotulinumtoxinA 200 UNITS/VIAL · VIAL, SINGLE-USE · Prescription
- BOTOX · OnabotulinumtoxinA 50 UNITS/VIAL · VIAL, SINGLE-USE · Prescription
- BOTOX COSMETIC · OnabotulinumtoxinA 50 UNITS/VIAL · VIAL, SINGLE-USE · Prescription
- BOTOX · OnabotulinumtoxinA 100 UNITS/VIAL · VIAL, SINGLE-USE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Onabotulinumtoxina" as an intervention, any sponsor and status, largest first.
- Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar LinesPivotal-lookingCompleted
Revance Therapeutics, Inc.Industry
NCT03004248 · 2,691 participants · Start Dec 9, 2016 · Primary completion Oct 17, 2018
Drug: Botulinum Toxins, Type A · For: Glabellar Frown Lines
Sites: Birmingham, Alabama; Beverly Hills, California; Encinitas, California · 61 sites in all
- Using Botox to Treat Patients With Idiopathic ClubfootStatus unknown
University of British ColumbiaAcademic, hospital or other
NCT00474032 · 2,000 participants (planned) · Start Mar 2003 · Primary completion Mar 2023
Drug: Botulinum Toxin (Type A) injection (10 U/Kg) · For: Clubfoot
Sites: Vancouver, Canada
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic MigrainePivotal-lookingActive, not recruiting
Merz Therapeutics GmbHIndustry
NCT07018700 · 997 participants · Start Aug 21, 2025 · Primary completion Mar 2027
Drug: Xeomin; Placebo · For: Episodic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 110 sites in all
- Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown LinesPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01189760 · 917 participants · Start Sep 1, 2010 · Primary completion Mar 1, 2011
Drug: onabotulinumtoxinA 24 U; onabotulinumtoxinA 44 U and 1 more · For: Facial Rhytides; Crow's Feet Lines; Glabellar Lines
Sites: Newport Beach, California; Vancouver, Canada; Antibes, France · 4 sites in all
- Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinencePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00915525 · 829 participants · Start Feb 1, 2010 · Primary completion Aug 5, 2014
Drug: botulinum toxin Type A · For: Overactive Bladder; Urinary Incontinence
Sites: Newport Beach, California; Ghent, Belgium; Victoria, Canada · 8 sites in all
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigrainePivotal-lookingActive, not recruiting
Merz Therapeutics GmbHIndustry
NCT07018713 · 808 participants · Start Aug 21, 2025 · Primary completion Mar 2027
Drug: Xeomin; Placebo · For: Chronic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 111 sites in all
- Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown LinesPivotal-lookingCompleted
Merz Pharmaceuticals GmbHIndustry
NCT00512135 · 801 participants · Start Jun 18, 2007 · Primary completion Dec 28, 2009
Drug: IncobotulinumtoxinA (Xeomin) (20 units) · For: Glabellar Lines
Sites: Los Angeles, California; Englewood, Colorado; Aventura, Florida · 25 sites in all
- Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in AdultsPivotal-lookingCompleted
AEON Biopharma, Inc.Industry
NCT04845178 · 797 participants · Start Mar 1, 2021 · Primary completion Jun 19, 2024
Drug: ABP-450; Placebo · For: Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Tempe, Arizona · 62 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective26,774
- off label use11,721
- therapeutic response decreased4,513
- headache4,135
- product preparation error3,646
- injection site pain3,468
- eyelid ptosis3,149
- multiple use of single-use product2,866
- migraine2,406
- nausea2,245
- pain1,921
- fatigue1,878
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 102 |
| 2005 | 102 |
| 2006 | 110 |
| 2007 | 146 |
| 2008 | 454 |
| 2009 | 341 |
| 2010 | 4,860 |
| 2011 | 1,455 |
| 2012 | 2,710 |
| 2013 | 3,065 |
| 2014 | 3,096 |
| 2015 | 3,398 |
| 2016 | 4,998 |
| 2017 | 4,233 |
| 2018 | 4,692 |
| 2019 | 6,167 |
| 2020 | 5,224 |
| 2021 | 5,623 |
| 2022 | 5,185 |
| 2023 | 7,533 |
| 2024 | 5,357 |
| 2025 | 5,319 |
| 2026 | 3,800 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Botox (Onabotulinumtoxina)
2024 spending
$122M
Beneficiaries
35,913
90,229 claims
Per beneficiary
$3,405
$1,034.36 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $58,026,492 |
| 2021 | $68,468,938 |
| 2022 | $90,961,370 |
| 2023 | $112,400,196 |
| 2024 | $122,282,695 |
Part B: Botox* (Onabotulinumtoxina*) · HCPCS J0585
2024 spending
$479M
Beneficiaries
165,103
403,331 claims
Per beneficiary
$2,899
2024 ASP limit $6.36 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $330,751,077 |
| 2021 | $366,441,061 |
| 2022 | $414,805,768 |
| 2023 | $444,518,571 |
| 2024 | $478,583,956 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review.
Shaterian N, Shaterian N, Ghanaatpisheh A, et al. · Pain Res Manag 2022 · Meta-Analysis, Systematic Review
- Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis.
Medrea I, Cooper P, Lagman-Bartolome AM, et al. · Can J Neurol Sci 2025 · Systematic Review, Meta-Analysis
- Botulinum toxin type A for facial wrinkles.
Camargo CP, Xia J, Costa CS, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- CGRP-targeted medication in chronic migraine - systematic review.
Oliveira R, Gil-Gouveia R, Puledda F · J Headache Pain 2024 · Systematic Review
- OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW, Turkel CC, DeGryse RE, et al. · Headache 2010 · Multicenter Study, Randomized Controlled Trial
- Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): Development, insights, and impact.
Lowe N, Naumann M, Eadie N · Medicine (Baltimore) 2023 · Randomized Controlled Trial
Sponsor: AbbVie · Also marketed as Botox
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.